Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-90
SponsorCheng-Hsin General Hospital
About this trial
Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
hospitalized for acute heart failure
Disqualifiers
initial serum NT-proBNP level <300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis
Trial population
Study participants were recruited from patients admitted to Cheng Hsin General Hospital with the major diagnosis of acute heart failure. After written informed consent was obtained (in compliance with the Helsinki Declaration), patients with age more than 20 were included. Exclusion criteria were initial serum NT-proBNP level \<300ng/ml, the presence of amputation, being pregnant, and receiving regular dialysis.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
major adverse cardiovascular events
mortality, acute myocardial infarction, acute stroke, and heart failure hospitalization
Time frame
1 yearSecondary outcomes
1
major adverse kidney events
mortality, new end-stage renal disease, and 30% decline in estimated GFR
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov